Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2015 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Oral Presentation of Firdapse Phase 3 Trial Data at American Academy of Neurology Annual Meeting (AAN)

CORAL GABLES, Fla., April 14, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and...
March 16, 2015 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2014 Financial Results

CORAL GABLES, Fla., March 16, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and...
March 09, 2015 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Present at the 27th Annual ROTH Conference

CORAL GABLES, Fla., March 9, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and...
March 05, 2015 10:35 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for Treatment of Congenital Myasthenic Syndromes

CORAL GABLES, Fla., March 5, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and...
February 19, 2015 12:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Appointment of Richard J. Daly and Donald A. Denkhaus to Its Board of Directors

CORAL GABLES, Fla., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and...
February 09, 2015 10:10 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners, Inc. Announces Closing of Previously Announced Public Offering

CORAL GABLES, Fla., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals) today reported that it has closed its previously announced public...
February 04, 2015 09:00 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners, Inc. Prices Public Offering of Common Stock

CORAL GABLES, Fla., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals) announced the pricing of its previously announced underwritten...
February 03, 2015 16:40 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners, Inc. Announces Commencement of Public Offering of Common Stock

CORAL GABLES, Fla., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals) announced today that it intends to offer shares of its common stock...
February 02, 2015 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Encouraging Pre-NDA Meeting With the FDA for Firdapse(TM) as a Treatment for Lambert-Eaton Myasthenic Syndrome (LEMS)

CORAL GABLES, Fla., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and...
January 12, 2015 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Provides an Update of 2015 Goals for Its Product Portfolio

Pre-NDA Meeting with the FDA Firdapse NDA Submission Developing Regulatory Strategy for Firdapse for Congenital Myasthenic Syndrome Hosting 1x1 Meetings in San Francisco January...